2019 tables: Institutions - life sciences - corporate

The 2019 tables are based on Nature Index data from 1 January 2018 to 31 December 2018.

Table criteria

# Institution Share 2017 Share 2018 Count 2018 Change in Adjusted Share 2017-2018*
1 Amgen Inc., United States of America (USA) 10.72 15.21 58 32.0%
2 Alphabet Inc., United States of America (USA) 4.48 13.77 37 185.8%
3 Pfizer Inc., United States of America (USA) 10.60 11.32 44 -0.7%
4 Merck & Co., Inc., United States of America (USA) 13.07 7.70 33 -45.2%
5 Regeneron Pharmaceuticals, Inc., United States of America (USA) 4.95 6.00 17 12.7%
6 IBM Corporation, United States of America (USA) 4.09 5.16 24 17.4%
7 Bristol-Myers Squibb (BMS), United States of America (USA) 4.03 5.00 25 15.2%
8 Leidos Holdings, Inc., United States of America (USA) 3.30 4.48 69 26.3%
9 Johnson & Johnson, United States of America (USA) 5.62 3.91 25 -35.4%
10 Eli Lilly and Company, United States of America (USA) 3.63 3.79 18 -2.9%
11 Ionis Pharmaceuticals, Inc., United States of America (USA) 3.44 3.48 20 -6.1%
12 Microsoft Corporation, United States of America (USA) 1.38 3.15 17 111.7%
13 Illumina, Inc., United States of America (USA) 3.18 3.09 15 -9.7%
14 AbbVie Inc., United States of America (USA) 4.96 2.62 13 -50.9%
15 H3 Biomedicine Inc., United States of America (USA) 2.58 2.47 7 -11.2%
16 Human Longevity, Inc., United States of America (USA) 3.74 2.44 8 -39.3%
17 D. E. Shaw Research, United States of America (USA) 0.08 2.30 5 2,461.4%
18 Gilead Sciences, Inc., United States of America (USA) 1.64 2.09 9 18.9%
19 Biogen Inc., United States of America (USA) 4.04 2.00 15 -53.9%
20 Corteva Agriscience, United States of America (USA) 2.00 2 N/A
21 Wellspring Biosciences, United States of America (USA) 1.90 2 N/A
22 New England Biolabs, Inc. (NEB), United States of America (USA) 3.63 1.79 6 -54.1%
23 Agios Pharmaceuticals, Inc., United States of America (USA) 0.58 1.64 6 160.2%
24 Integral Molecular, Inc., United States of America (USA) 0.11 1.56 5 1,251.0%
25 Thermo Fisher Scientific Inc., United States of America (USA) 1.75 1.51 12 -20.1%
26 HP Inc., United States of America (USA) 1.46 3 N/A
27 HRL Laboratories LLC, United States of America (USA) 1.13 1.40 2 15.7%
28 23andMe, Inc., United States of America (USA) 1.55 1.36 18 -18.6%
29 Pacific Biosciences of California, Inc., United States of America (USA) 0.88 1.33 10 41.5%
30 GeneDx Inc., United States of America (USA) 0.96 1.26 23 21.2%
31 Genesis Biotechnology Group, United States of America (USA) 1.25 2 N/A
32 Alnylam Pharmaceuticals, Inc., United States of America (USA) 0.37 1.17 2 190.3%
33 EpiCypher, Inc., United States of America (USA) 1.11 3 N/A
34 Cancer Prevention Pharmaceuticals, Inc. (CPP), United States of America (USA) 1.00 1 N/A
34 Advaxis Immunotherapies, United States of America (USA) 1.00 1 N/A
34 Synlogic, United States of America (USA) 1.00 1 N/A
34 Dynavax Technologies Corp., United States of America (USA) 1.00 1 N/A
34 Navitor Pharmaceuticals, Inc., United States of America (USA) 1.00 1 N/A
34 Synthetic Genomics, Inc. (SGI), United States of America (USA) 2.30 1.00 1 -59.6%
35 Aduro BioTech, Inc., United States of America (USA) 0.07 0.98 3 1,173.8%
36 Agenus Inc., United States of America (USA) 0.92 2 N/A
37 Embark Veterinary, Inc., United States of America (USA) 0.90 1 N/A
38 InSilixa, Inc., United States of America (USA) 0.90 1 N/A
39 Mars, Incorporated (Mars), United States of America (USA) 0.87 2 N/A
40 INDIGO Biosciences, Inc., United States of America (USA) 0.83 1 N/A
41 Promega Corporation, United States of America (USA) 0.82 3 N/A
42 InterX, Inc., United States of America (USA) 0.80 1 N/A
43 Foundation Medicine, Inc., United States of America (USA) 2.15 0.76 4 -66.9%
44 In Vivo Analytics, Inc., United States of America (USA) 0.75 1 N/A
44 Sigmovir Biosystems, Inc. (SBI), United States of America (USA) 0.75 1 N/A
45 E. I. du Pont de Nemours and Company (DuPont), United States of America (USA) 1.89 0.74 10 -63.4%
46 Personal Genome Diagnostics, Inc. (PGDx), United States of America (USA) 0.07 0.72 1 852.1%
47 Confluence Discovery Technologies, Inc., United States of America (USA) 0.72 2 N/A
48 Arbor Biotechnologies, Inc., United States of America (USA) 0.71 1 N/A
49 Becton, Dickinson and Company (BD), United States of America (USA) 0.35 0.71 3 88.1%
50 SQZ Biotechnologies Company, United States of America (USA) 0.71 1 N/A

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals, selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at natureindex.com.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2020 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.